Pharmaceuticals · EMCURE
Pharma - Formulators
from 1,937 today
Emcure delivered a better-than-expected financial performance in 1QFY27, driven by robust execution across focus segments. We expect 15%/21%/25% CAGR in revenue/EBITDA/PAT over FY26-28 and reiterate BUY with a target price of INR2,300.
Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.
